These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38302765)

  • 1. Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials.
    Phillips-Beyer A; Kawata AK; Kleinman L; Seboek Kinter D; Flamion B
    Pharmaceut Med; 2024 Mar; 38(2):133-144. PubMed ID: 38302765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant.
    Phillips-Beyer A; Kawata AK; Kleinman L; Kinter DS
    Pharmaceut Med; 2023 Jul; 37(4):291-303. PubMed ID: 37286927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
    Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
    Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
    Arnold V; Ancoli-Israel S; Dang-Vu TT; Mishima K; Pinner K; Malhotra M; Moline M
    Neurol Ther; 2024 Aug; 13(4):1081-1098. PubMed ID: 38748321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
    Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
    Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials.
    Huang Z; Zhan S; Chen C; Zhang R; Zhou Y; He J; Lin Z; Bao C; Zhu S; Zhao J; Zhang S; Jiang Y; Wang Y
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37875349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study.
    Li Y; Zhang R; Zhou Y; Bao C; Lin Z; Chen C; He J; Jin Z; Song L; Zhang M; Guo S; Jiang Y; Zhao Z
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37864827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
    Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
    CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.
    Di Marco T; Scammell TE; Meinel M; Seboek Kinter D; Datta AN; Zammit G; Dauvilliers Y
    CNS Drugs; 2023 Jul; 37(7):639-653. PubMed ID: 37477771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the single-item Patient Global Impression-Severity scale as a self-reported assessment of insomnia severity.
    Snyder ES; Tao P; Svetnik V; Lines C; Herring WJ
    J Sleep Res; 2021 Feb; 30(1):e13141. PubMed ID: 33210445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
    Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.
    Lankford A; Rogowski R; Essink B; Ludington E; Heith Durrence H; Roth T
    Sleep Med; 2012 Feb; 13(2):133-8. PubMed ID: 22197474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).
    Hudgens S; Phillips-Beyer A; Newton L; Seboek Kinter D; Benes H
    Patient; 2021 Mar; 14(2):249-268. PubMed ID: 33131027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of suanzaoren decoction for chronic insomnia disorder in adults: study protocol for randomised, double-blind, double-dummy, placebo-controlled trial.
    Zhou QH; Wang HL; Zhou XL; Xu MB; Zhang HF; Huang LB; Zheng GQ; Lin Y
    BMJ Open; 2017 Apr; 7(4):e014280. PubMed ID: 28377394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.
    Hajak G; Hedner J; Eglin M; Loft H; Stórustovu SI; Lütolf S; Lundahl J;
    Sleep Med; 2009 Aug; 10(7):705-12. PubMed ID: 19346160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.